Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine
Clinical trial NCT04672473 · UNKNOWN
Trial details
- NCT number
- NCT04672473
- Sponsor
- Shenzhen University General Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-30
- Primary completion
- 2023-07-28
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.